Autologous bone marrow transplantation in relapses of chemotherapy-sensitive aggressive non-Hodgkin's lymphoma: long-term outcome.
Eleven patients with relapsed intermediate to high grade non-Hodgkin's lymphoma (NHL) responding to induction treatment were treated with high-dose chemotherapy (CBV or ICBV conditioning regimen) plus autologous bone marrow transplantation as early consolidation treatment. At 6 years, relapse-free survival is 27.3% and overall survival is 36.4%. Patients with bone marrow involvement from NHL before the induction therapy did not have a worse prognosis. Despite the long-term follow-up, no secondary myelodysplasia or acute leukemia occurred in our patients. Within the limitations of patient number and selection, our retrospective study confirms the importance of tumor responsiveness and long-term follow-up. Patients with relapsed, but chemotherapy-sensitive NHL can achieve prolonged survival after high-dose chemotherapy plus autologous bone marrow transplantation.
Lalle
M
M
Hematology Division, San Camillo Hospital, Rome, Italy.
Montuoro
A
A
D016026:Bone Marrow Transplantation; D004358:Drug Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality / Q000628:therapy*; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous